Recent Material Events - Genvec, Inc (GNVC)

Filing Date	Description
2008-06-06	On June 6, 2008, GenVec, Inc., a Delaware corporation (“GenVec”), entered into purchase agreements with investors (“Investor Purchase Agreements”) relating to the issuance and sale by GenVec of up to 11,258,279 shares (the “S ...
2008-06-02	On May 29, 2008, Mark Thornton, M.D., Ph.D., Senior Vice President of Product Development of GenVec, Inc. (“GenVec”), delivered a presentation to the American Society of Gene Therapy regarding TNFerade™ clinical development, i ...
2008-01-18	On January 16, 2008, the board of directors of GenVec, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the board to seven seats and appointed Kevin M. Rooney to the b ...
2008-01-08	On January 3, 2008, GenVec, Inc. issued a press release regarding protocol changes for its TNFerade Phase II/III pancreatic cancer clinical trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. ...
2007-11-07	On November 7, 2007, GenVec, Inc. (“GenVec”) issued a press release announcing its financial results for the period ended September 30, 2007. GenVec’s press release is furnished as Exhibit 99.1 hereto, and is incorporated herein by ref ...
2007-09-21	On September 19, 2007, Harold R. Werner informed the board of directors of GenVec, Inc. (the “Company”) that he would resign from the board of directors effective September 30, 2007. ...
2007-03-14	On March 14, 2007, GenVec, Inc. (“GenVec”) issued a press release announcing its financial results for the three-month and twelve-month periods ended December 31, 2006.... ...
2007-02-01	On January 30, 2007, GenVec, Inc. (the “Company”) entered into an agreement with the United States Department of Homeland Security (“DHS”). The agreement provides up to $15.1 million over three years, comprised of an initial $6.0... ...
2006-12-20	On December 19, 2006, GenVec, Inc. (the “Company”) entered into a letter agreement (the “Placement Agent Agreement”) with Rodman & Renshaw, LLC as placement agent, relating to the proposed offering of up to 9,609,757 shares o... ...
2006-12-19	On December 19, 2006, the Company issued a press release announcing initial, interim efficacy data for its TNFerade Phase II/III pancreatic cancer clinical trial. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is in... ...